Meeting
2020 Genitourinary Cancers Symposium
Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer.
Authors
Cristina Suarez Rodriguez
Vall d’Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain
Cristina Suarez Rodriguez , James M. G. Larkin , Poulam Patel , Begona Pérez Valderrama , Alejo Rodriguez-Vida , Hilary Glen , Fiona Thistlethwaite , Christy Ralph , Gopalakrishnan Srinivasan , Maria Jose José Mendez Vidal , Abigail Carter , Charlotte Tyson , Aaron Prendergast , Kelly Mousa , Thomas Powles
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02819596
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 619)
Abstract #
619
Poster Bd #
D5
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.
First Author: Cristina Suarez Rodriguez
First Author: Francesca Jackson-Spence
Poster
2019 ASCO Annual Meeting
A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS 0415).
First Author: Viktor Grünwald
Poster
2017 ASCO Annual Meeting
Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use.
First Author: Robert L. Ferris